0001819934-25-000001.txt : 20250207 0001819934-25-000001.hdr.sgml : 20250207 20250207150817 ACCESSION NUMBER: 0001819934-25-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250207 DATE AS OF CHANGE: 20250207 EFFECTIVENESS DATE: 20250207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ambagon Therapeutics Inc. CENTRAL INDEX KEY: 0001819934 ORGANIZATION NAME: IRS NUMBER: 850560627 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-537701 FILM NUMBER: 25601234 BUSINESS ADDRESS: STREET 1: 953 INDIANA STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (415) 235-6373 MAIL ADDRESS: STREET 1: 953 INDIANA STREET CITY: SAN FRANCISCO STATE: CA ZIP: 94107 FORMER COMPANY: FORMER CONFORMED NAME: AmbAgon Therapeutics Inc. DATE OF NAME CHANGE: 20200803 D 1 primary_doc.xml X0708 D LIVE 0001819934 Ambagon Therapeutics Inc. De Lismortel 31, Catalyst Business Ctr Eindhoven P7 NETHERLANDS 5612 AR 31 40 7517694 DELAWARE AmbAgon Therapeutics Inc. Corporation true 2020 Melissa McCracken c/o Ambagon Therapeutics Inc. De Lismortel 31, Catalyst Business Ctr. Eindhoven P7 NETHERLANDS 5612 AR Director Christian Ottmann c/o Ambagon Therapeutics Inc. De Lismortel 31, Catalyst Business Ctr. Eindhoven P7 NETHERLANDS 5612 AR Executive Officer Josh Seidenfeld c/o Cooley LLP 3175 Hanover Street Palo Alto CA CALIFORNIA 94304 Executive Officer Biotechnology Decline to Disclose 06b false 2025-01-24 false true false 0 12000000 5000000 7000000 Series A-1 Preferred Stock and shares of the Company's Common Stock issuable upon the conversion thereof. false 4 0 0 0 false Ambagon Therapeutics Inc. /s/ Christian Ottmann Christian Ottmann Interim Chief Executive Officer 2025-02-07